Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
BRISBANE, Calif., May 02, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by UNITY. The Company has also granted the underwriters a 30-day option to purchase from the Company an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. UNITY’s common stock has been approved for listing on The Nasdaq Global Select Market and is expected to begin trading under the ticker symbol “UBX” on May 3, 2018. The offering is expected to close on May 7, 2018, subject to customary closing conditions.
Goldman Sachs & Co. LLC, Morgan Stanley and Citigroup acted as joint book-running managers for the offering. Mizuho Securities acted as a lead manager for the offering.
A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on May 2, 2018. The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained from (1) Goldman Sachs & Co. LLC., Attention: Prospectus Department, 200 West Street, New York, NY 10282, Telephone: 1-866-471-2526; (2) Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; and (3) Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 1-800-831-9146.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About UNITY Biotechnology, Inc.
UNITY Biotechnology is developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related afflictions, such as osteoarthritis, eye diseases and pulmonary diseases. UNITY's seasoned management team has experience building companies and developing medicines.
Contact: Investors Bob Goeltz [email protected] 1-650-525-4980 Media Canale Communications Jason Spark [email protected] 1-619-849-6005
